Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
The price of Summit Therapeutics Inc (NASDAQ: SMMT) closed at $17.49 in the last session, down -1.63% from day before closing price of $17.78. In other words, the price has decreased by -$1.63 from its previous closing price. On the day, 1.46 million shares were traded. SMMT stock price reached its highest trading level at $17.84 during the session, while it also had its lowest trading level at $17.42.
Ratios:
We take a closer look at SMMT’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.80 and its Current Ratio is at 3.80. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.01.
On September 17, 2025, Barclays started tracking the stock assigning a Underweight rating and target price of $13.Barclays initiated its Underweight rating on September 17, 2025, with a $13 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Oct 21 ’25 when Xia Yu bought 533,617 shares for $18.74 per share. The transaction valued at 9,999,983 led to the insider holds 32,057,147 shares of the business.
DUGGAN ROBERT W bought 26,680 shares of SMMT for $499,983 on Oct 21 ’25. The Co-Chief Executive Officer now owns 76,680 shares after completing the transaction at $18.74 per share. On Oct 21 ’25, another insider, Zanganeh Mahkam, who serves as the Co-Chief Executive Officer of the company, bought 26,680 shares for $18.74 each. As a result, the insider paid 499,983 and bolstered with 76,680 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SMMT now has a Market Capitalization of 13020300288 and an Enterprise Value of 12787174400.
Stock Price History:
The Beta on a monthly basis for SMMT is -1.52, which has changed by -0.031062663 over the last 52 weeks, in comparison to a change of 0.17673707 over the same period for the S&P500. Over the past 52 weeks, SMMT has reached a high of $36.91, while it has fallen to a 52-week low of $15.55. The 50-Day Moving Average of the stock is -3.02%, while the 200-Day Moving Average is calculated to be -20.00%.
Shares Statistics:
According to the various share statistics, SMMT traded on average about 2.86M shares per day over the past 3-months and 2141500 shares per day over the past 10 days. A total of 744.44M shares are outstanding, with a floating share count of 102.73M. Insiders hold about 86.17% of the company’s shares, while institutions hold 14.08% stake in the company. Shares short for SMMT as of 1765756800 were 35753740 with a Short Ratio of 12.51, compared to 1763078400 on 31236590. Therefore, it implies a Short% of Shares Outstanding of 35753740 and a Short% of Float of 30.19.
Earnings Estimates
A detailed examination of Summit Therapeutics Inc (SMMT) is currently in progress, with 11.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$0.08, with high estimates of $0.71 and low estimates of -$0.29.
Analysts are recommending an EPS of between -$0.1 and -$1.12 for the fiscal current year, implying an average EPS of -$0.77. EPS for the following year is -$0.75, with 10.0 analysts recommending between -$0.43 and -$1.18.
